BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

12 Feb 2024 07:00:53 By Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 07:00:48 By Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

05 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2024 16:01:59 By Nasdaq GlobeNewswire

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:00:50 By Nasdaq GlobeNewswire

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

19 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2023 16:01:42 By Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

29 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

21 Nov 2023 16:01:44 By Nasdaq GlobeNewswire

BioCryst Launches ORLADEYO® (berotralstat) in Spain

21 Nov 2023 07:00:13 By Nasdaq GlobeNewswire

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

10 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Nov 2023 16:01:28 By Nasdaq GlobeNewswire

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

03 Nov 2023 12:03:00 By Nasdaq GlobeNewswire

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

03 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

02 Nov 2023 07:00:55 By Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

27 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

26 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Host R&D Day on November 3

20 Oct 2023 07:00:08 By Nasdaq GlobeNewswire

BioCryst to Report Third Quarter 2023 Financial Results on November 2

19 Oct 2023 07:00:16 By Nasdaq GlobeNewswire